48 patents
Utility
CD80 Variant Immunomodulatory Proteins and Uses Thereof
4 Jan 24
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker, Mark F. Maurer, Dan Ardourel, Daniel William Demonte, Joseph L. Kuijper
Filed: 10 Mar 23
Utility
CD112 variant immunomodulatory proteins and uses thereof
5 Dec 23
Provided herein are immunomodulatory proteins comprising variant CD112 and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker, Daniel William Demonte, Mark F. Maurer, Dan Ardourel, Joseph L. Kuijper
Filed: 27 Jul 17
Utility
CD155 Variant Immunomodulatory Proteins and Uses Thereof
30 Nov 23
Provided herein are immunomodulatory proteins comprising variant CD155 and nucleic acids encoding such proteins.
Ryan SWANSON, Michael KORNACKER, Daniel William DEMONTE, Mark F. MAURER
Filed: 14 Oct 22
Utility
CTLA-4 variant immunomodulatory proteins and uses thereof
12 Sep 23
Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins.
Lawrence Evans, Joseph L. Kuijper, Ryan Swanson
Filed: 9 Oct 18
Utility
PD-L2 variant immunomodulatory proteins and uses thereof
22 Aug 23
Provided herein are immunomodulatory proteins comprising variant PD-L2 and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker, Mark F. Maurer, Dan Ardourel, Daniel William Demonte, Joseph L. Kuijper
Filed: 13 Mar 18
Utility
CTLA-4 Variant Immunomodulatory Proteins and Uses Thereof
10 Aug 23
Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins.
Lawrence EVANS, Joseph L. Kuijper, Ryan Swanson
Filed: 30 Jan 23
Utility
April and Baff Inhibitory Immunomodulatory Proteins with and without a T Cell Inhibitory Protein and Methods of Use Thereof
3 Aug 23
Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers) alone, or also coupled with inhibition of T cell costimulation.
Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG, Ryan SWANSON
Filed: 7 May 21
Utility
Variant Icos Ligand Immunomodulatory Proteins and Related Compositions and Methods
27 Jul 23
Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins.
Lawrence Evans, Michael Kornacker, Ryan Swanson
Filed: 21 Feb 23
Utility
PD-L1 Variant Immunomodulatory Proteins and Uses Thereof
13 Jul 23
Provided herein are immunomodulatory proteins comprising variant PD-L1 and nucleic acids encoding such proteins.
Ryan SWANSON, Michael KORNACKER, Mark F. MAURER, Dan ARDOUREL, Daniel William DEMONTE, Joseph L. KUJIPER
Filed: 13 Mar 18
Utility
CD80 Variant Immunomodulatory Proteins and Uses Thereof
4 May 23
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins.
Ryan SWANSON, Michael KORNACKER
Filed: 7 Oct 22
Utility
CD80 variant immunomodulatory proteins and uses thereof
2 May 23
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker, Mark F. Maurer, Joseph L. Kuijper
Filed: 13 Mar 18
Utility
Multi-domain Immunomodulatory Proteins and Methods of Use Thereof
30 Mar 23
Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins.
Ryan SWANSON
Filed: 3 Jan 19
Utility
Variant ICOS ligand immunomodulatory proteins and related compositions and methods
28 Mar 23
Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins.
Lawrence Evans, Michael Kornacker, Ryan Swanson
Filed: 22 Dec 21
Utility
CD86 Variant Immunomodulatory Proteins and Uses Thereof
24 Nov 22
Provided herein are variant CD86 polypeptides, immunomodulatory proteins comprising variant CD86 polypeptides, and nucleic acids encoding such proteins.
Ryan SWANSON, Dan ARDOUREL, Steven Dennis LEVIN, Joseph L. KUIJPER
Filed: 27 Nov 19
Utility
CD80 variant immunomodulatory proteins and uses thereof
15 Nov 22
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker
Filed: 2 Feb 22
Utility
CD80 variant immunomodulatory proteins and uses thereof
25 Oct 22
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker
Filed: 2 Feb 22
Utility
CD155 variant immunomodulatory proteins and uses thereof
18 Oct 22
Provided herein are immunomodulatory proteins comprising variant CD155 and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker, Daniel William Demonte, Mark F. Maurer
Filed: 27 Jul 17
Utility
Immunomodulatory Proteins with Tunable Affinities
4 Aug 22
Provided are immunomodulatory proteins and nucleic acids encoding such proteins.
Ryan SWANSON, Michael KORNACKER
Filed: 29 Mar 22
Utility
Methods and Uses of Variant Icos Ligand (Icosl) Fusion Proteins
14 Jul 22
Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins.
Ryan SWANSON, Jing YANG, Stanford PENG, Jan HILLSON
Filed: 16 Apr 20
Utility
CD80 variant immunomodulatory proteins and uses thereof
14 Jun 22
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins.
Ryan Swanson, Michael Kornacker
Filed: 11 Jun 21